News - Zaltrap, Celgene

Filter

Current filters:

ZaltrapCelgene

Popular Filters

1 to 25 of 108 results

Second collaboration between FORMA Therapeutics and Celgene

02-04-2014

Privately-held drug discovery firm FORMA Therapeutics has entered a second strategic collaboration and…

BiotechnologyCelgeneFORMA TherapeuticsLicensingMergers & AcquisitionsResearch

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

01-04-2014

The global pancreatic cancer treatment market value in the six major countries (6MM: the USA, France,…

AbraxaneBiotechnologyCelgeneEuropeMarkets & MarketingOncologyUSA

NICE final guidance again rejects Sanofi’s Zaltrap for colorectal cancer

25-03-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE), today issued final guidance…

Northern EuropeOncologyPharmaceuticalPricingRegulationSanofiUKZaltrap

Positive Ph III results with oral Otezla in skin, nail and scalp of patients with plaque psoriasis

24-03-2014

US biotech firm Celgene has released positive new research findings on Otezla (apremilast), an oral,…

apremilastBiotechnologyCelgeneDermatologicalsOtezlaResearch

Celgene’s Otezla is first oral therapy OKed by FDA for adults with active psoriatic arthritis

23-03-2014

The US Food and Drug Administration on Friday approved US biotech firm Celgene’s Otezla (apremilast),…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneNorth AmericaOtezlaRegulationUSA

New survey confirms psoriasis and psoriatic arthritis patients frequently undertreated or not treated at all

21-03-2014

A unique and extensive survey provides the first-of-its-kind multinational look into the impact psoriasis…

Anti-Arthritics/RheumaticsCelgeneDermatologicalsHealthcarePharmaceutical

Celgene UK and Ireland appoint Rob Moore as Inflammation and Immunology Business Unit Director

Celgene UK and Ireland appoint Rob Moore as Inflammation and Immunology Business Unit Director

19-03-2014

Celgene UK and Ireland have announced the appointment of Rob Moore as the new Inflammation and Immunology…

BiotechnologyBoardroomCelgeneNorthern EuropeUK

NICE says better information needed on Celgene’s MM drug

NICE says better information needed on Celgene’s MM drug

14-03-2014

The UK drugs watchdog, the National Institute for Health and care Excellence (NICE) says that, based…

BiotechnologyCelgeneNorthern EuropeOncologyPricingRegulationRevlimidUK

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

Health Canada approves Celgene’s Pomalyst for multiple myeloma

Health Canada approves Celgene’s Pomalyst for multiple myeloma

12-02-2014

Regulatory agency Health Canada has approved US biotech firm Celgene’s drug Pomalyst (pomalidomide…

BiotechnologyCanadaCelgeneNorth AmericaOncologyPomalystRegulation

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Whistleblower law suit against Celgene unsealed

Whistleblower law suit against Celgene unsealed

07-02-2014

A US federal court yesterday unsealed a whistleblower/false claims law suit brought against US biotech…

BiotechnologyCelgeneLegalMarkets & MarketingNorth AmericaOncologyRevlimidThalomidUSA

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Celgene profits hit by higher R&D, acquisition costs

Celgene profits hit by higher R&D, acquisition costs

31-01-2014

US biotech major Celgene reported financial results for the fourth-quarter and full-year 2013, with final…

BiotechnologyCelgeneFinancial

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

18-01-2014

US biotech firm Celgene’s breast cancer drug, Abraxane (nanoparticle albumin-bound paclitaxel), has…

AbraxaneBiotechnologyCelgeneOncologyResearchSpecialised Therapeutics Australia

NantBioScience enters cancer collaboration with Celgene

NantBioScience enters cancer collaboration with Celgene

14-01-2014

USA-based NantBioScience, a subsidiary of privately-held NantWorks, has entered into a strategic collaboration…

AbraxaneBiotechnologyCelgeneLicensingNantBioSciencesNTB-010NTB-011OncologyResearch

Epizyme shares soar as Celgene deal triggers $25 million milestone payment

Epizyme shares soar as Celgene deal triggers $25 million milestone payment

08-01-2014

US biotech company Epizyme has announced the achievement of the proof of concept milestone in the EPZ-5676…

BiotechnologyCelgeneEpizymeFinancialOncologyResearchUSA

Celgene’s Abraxane given European approval for pancreatic cancer

Celgene’s Abraxane given European approval for pancreatic cancer

07-01-2014

US biotech company Celgene’s European subsidiary today announced that the European Commission has granted…

AbraxaneCelgeneEuropeOncologyPharmaceuticalRegulation

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Agios extends cancer metabolism accord with Celgene

Agios extends cancer metabolism accord with Celgene

12-12-2013

Metabolism specialist Agios Pharmaceuticals has announced an extension of one additional year to the…

Agios PharmaceuticalsBiotechnologyCelgeneLicensingOncologyResearch

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene

04-12-2013

US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Celgene’s Abraxane gets positive CHMP opinion for pancreatic cancer

Celgene’s Abraxane gets positive CHMP opinion for pancreatic cancer

29-11-2013

US biotech company Celgene’s (Nasdaq: CELG) European subsidiary has received a positive opinion from…

AbraxaneCelgeneEuropeOncologyPharmaceuticalRegulation

Celgene 3rd-qtr beats expectations; raises earnings guidance

25-10-2013

US biotech company Celgene Corp reported third quarter 2013 total revenue of $1.67 billion compared to…

BiotechnologyCelgeneFinancialHematologyOncology

1 to 25 of 108 results

Back to top